Clinical Trials
55 trialsBlinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL
Institute of Hematology & Blood Diseases Hospital, China
Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Karolinska University Hospital
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
Northside Hospital, Inc.
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Stanford University
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
St. Jude Children's Research Hospital
Interfant-21
Princess Maxima Center for Pediatric Oncology
Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center
Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
The First Affiliated Hospital of Soochow University
LAL-2025
PETHEMA Foundation
Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage
Institute of Hematology & Blood Diseases Hospital, China
GRAALL-2024
Assistance Publique - Hôpitaux de Paris
FORUM2
Bambino Gesù Hospital and Research Institute
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
Institute of Hematology & Blood Diseases Hospital, China
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
ALL Backbone in AYAs
Dana-Farber Cancer Institute
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
St. Jude Children's Research Hospital
CAMS-Ph+ B-ALL
Institute of Hematology & Blood Diseases Hospital, China
CCCG-LR-B-ALL
Institute of Hematology & Blood Diseases Hospital, China
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
St. Jude Children's Research Hospital
Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
Goethe University
Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation
First Affiliated Hospital of Zhejiang University
Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia
City of Hope Medical Center
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
University Hospital Schleswig-Holstein
CCCG-I/HR-ALL
Institute of Hematology & Blood Diseases Hospital, China
Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL
Cedars-Sinai Medical Center
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
Gruppo Italiano Malattie EMatologiche dell'Adulto
LAL2317
Gruppo Italiano Malattie EMatologiche dell'Adulto
Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL
First Affiliated Hospital of Zhejiang University
HOVON146ALL
Stichting Hemato-Oncologie voor Volwassenen Nederland
Blina-CELL
Institute of Hematology and Blood Transfusion, Czech Republic
BEAT-ALL-2024
The First Affiliated Hospital of Soochow University
DLI-TARGET
Ludwig-Maximilians - University of Munich
ABC
Nanfang Hospital, Southern Medical University
ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT
St. Anna Kinderkrebsforschung
Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab
Zhejiang University
Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab Consolidation
The Children's Hospital of Zhejiang University School of Medicine
Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia
Goethe University
Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)
Seoul National University Hospital